A common solution to group 2 influenza virus neutralization

The discovery and characterization of broadly neutralizing antibodies (bnAbs) against influenza viruses have raised hopes for the development of monoclonal antibody (mAb)-based immunotherapy and the design of universal influenza vaccines. Only one human bnAb (CR8020) specifically recognizing group 2...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Friesen, Robert H. E., Lee, Peter S., Stoop, Esther J. M., Hoffman, Ryan M. B., Ekiert, Damian C., Bhabha, Gira, Yu, Wenli, Juraszek, Jarek, Koudstaal, Wouter, Jongeneelen, Mandy, Korse, Hans J. W. M., Ophorst, Carla, Brinkman-van der Linden, Els C. M., Throsby, Mark, Kwakkenbos, Mark J., Bakker, Arjen Q., Beaumont, Tim, Spits, Hergen, Kwaks, Ted, Vogels, Ronald, Ward, Andrew B., Goudsmit, Jaap, Wilson, Ian A.
Format: Artigo
Idioma:Inglês
Publicat: National Academy of Sciences 2014
Matèries:
Biological Sciences
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3890827/
https://ncbi.nlm.nih.gov/pubmed/24335589
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1073/pnas.1319058110
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars